Neurohumoral modulation of metalloproteinases in cardiac failure: impact on remodeling

[1]  D. Kass,et al.  beta-blockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin II combined with evolving cardiac dysfunction. , 2000, Circulation research.

[2]  Y. Yazaki,et al.  Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. , 1999, Circulation.

[3]  Paul Smolen,et al.  Effects of macromolecular transport and stochastic fluctuations on dynamics of genetic regulatory systems. , 1999, American journal of physiology. Cell physiology.

[4]  K. Baker,et al.  The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? , 1999, Circulation research.

[5]  M. Zile,et al.  Matrix metalloproteinase inhibition during the development of congestive heart failure : effects on left ventricular dimensions and function. , 1999, Circulation research.

[6]  P. Libby,et al.  Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. , 1999, Circulation.

[7]  L. Mestroni,et al.  Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol , 1999 .

[8]  G. Butler,et al.  Mechanisms for pro matrix metalloproteinase activation , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[9]  Y. Sun,et al.  Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. , 1998, Circulation.

[10]  Z. Galis,et al.  Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations. , 1998, American journal of physiology. Heart and circulatory physiology.

[11]  P. Vokonas,et al.  Prospective study of a self-report type A scale and risk of coronary heart disease: test of the MMPI-2 type A scale. , 1998, Circulation.

[12]  J. S. Janicki,et al.  ANG II-related myocardial damage: role of cardiac sympathetic catecholamines and β-receptor regulation. , 1998, American journal of physiology. Heart and circulatory physiology.

[13]  Simon C Watkins,et al.  Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells. , 1998, Circulation.

[14]  F. Spinale,et al.  Increased Matrix Metalloproteinase Activity and Selective Upregulation in LV Myocardium From Patients With End-Stage Dilated Cardiomyopathy , 1998 .

[15]  Z. Galis,et al.  Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. , 1998, American journal of physiology. Heart and circulatory physiology.

[16]  Q. Li,et al.  Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. , 1998, The Journal of clinical investigation.

[17]  D. Kass,et al.  Synergistic exacerbation of diastolic stiffness from short-term tachycardia-induced cardiodepression and angiotensin II. , 1998, Circulation research.

[18]  F. Spinale,et al.  Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. , 1998, Circulation research.

[19]  G. Lamas,et al.  Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. , 1997, Circulation.

[20]  R. A. Hunt,et al.  Molecular mechanisms of angiotensin II in modulating cardiac function: intracardiac effects and signal transduction pathways. , 1997, Journal of molecular and cellular cardiology.

[21]  Bertram Pitt,et al.  Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) , 1997, The Lancet.

[22]  S. Shapiro,et al.  Mighty mice: transgenic technology "knocks out" questions of matrix metalloproteinase function. , 1997, Matrix biology : journal of the International Society for Matrix Biology.

[23]  K. Lindpaintner,et al.  Local stress, not systemic factors, regulate gene expression of the cardiac renin-angiotensin system in vivo: a comprehensive study of all its components in the dog. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Redfield,et al.  Angiotensin II in the evolution of experimental heart failure. , 1996, Hypertension.

[25]  M. Quiñones,et al.  Relation of ventricular size and function to heart failure status and ventricular dysrhythmia in patients with severe left ventricular dysfunction. , 1996, The American journal of cardiology.

[26]  J. S. Janicki,et al.  Catecholamine response to chronic ANG II infusion and its role in myocyte and coronary vascular damage. , 1995, The American journal of physiology.

[27]  W. Stetler-Stevenson,et al.  Quantitative zymography: detection of picogram quantities of gelatinases. , 1994, Analytical biochemistry.

[28]  P. Armstrong,et al.  Structural remodelling in heart failure: gelatinase induction. , 1994, The Canadian journal of cardiology.

[29]  J. Sadoshima,et al.  Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro , 1993, Cell.

[30]  J. Sadoshima,et al.  Critical Role of the AT1 Receptor Subtype , 2005 .

[31]  P. Armstrong,et al.  Remodeling and reparation of the cardiovascular system. , 1992, Journal of the American College of Cardiology.

[32]  J. S. Janicki,et al.  Cardiac myocyte necrosis induced by angiotensin II. , 1991, Circulation research.

[33]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[34]  K. Weber,et al.  Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System , 1991, Circulation.

[35]  J. Woessner,et al.  Matrix metalloproteinases and their inhibitors in connective tissue remodeling , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  C. Lapière,et al.  Collagenolytic activity in amphibian tissues: a tissue culture assay. , 1962, Proceedings of the National Academy of Sciences of the United States of America.

[37]  S. Goldstein,et al.  Ventricular Remodeling and Angiotensin‐Converting Enzyme Inhibitors , 1994, Journal of cardiovascular pharmacology.

[38]  H. Birkedal‐Hansen,et al.  Matrix metalloproteinases: a review. , 1993, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.